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Abstract
Background: Radiotherapy (RT) is the primary treatment modality for inoperable, locally advanced non-small-cell lung
cancer (NSCLC), but even with highly conformal treatment planning, radiation pneumonitis (RP) remains the most serious,
dose-limiting complication. Previous clinical reports proposed that cytokine plasma levels measured during RT allow to
estimate the individual risk of patients to develop RP. The identification of such cytokine risk profiles would facilitate
tailoring radiotherapy to maximize treatment efficacy and to minimize radiation toxicity. However, cytokines are produced
not only in normal lung tissue after irradiation, but are also over-expressed in tumour cells of NSCLC specimens. This
tumour-derived cytokine production may influence circulating plasma levels in NSCLC patients. The aim of the present
study was to investigate the prognostic value of TNF-a, IL-1b, IL-6 and TGF-b1 plasma levels to predict radiation
pneumonitis and to evaluate the impact of tumour-derived cytokine production on circulating plasma levels in patients
irradiated for NSCLC.
Methodology/Principal Findings: In 52 NSCLC patients (stage I–III) cytokine plasma levels were investigated by ELISA
before and weekly during RT, during follow-up (1/3/6/9 months after RT), and at the onset of RP. Tumour biopsies were
immunohistochemically stained for IL-6 and TGF-b1, and immunoreactivity was quantified (grade 1–4). RP was evaluated
according to LENT-SOMA scale. Tumour response was assessed according to RECIST criteria by chest-CT during follow-up. In
our clinical study 21 out of 52 patients developed RP (grade I/II/III/IV: 11/3/6/1 patients). Unexpectedly, cytokine plasma
levels measured before and during RT did not correlate with RP incidence. In most patients IL-6 and TGF-b1 plasma levels
were already elevated before RT and correlated significantly with the IL-6 and TGF-b1 production in corresponding tumour
biopsies. Moreover, IL-6 and TGF-b1 plasma levels measured during follow-up were significantly associated with the
individual tumour responses of these patients.
Conclusions/Significance: The results of this study did not confirm that cytokine plasma levels, neither their absolute nor
any relative values, may identify patients at risk for RP. In contrast, the clear correlations of IL-6 and TGF-b1 plasma levels
with the cytokine production in corresponding tumour biopsies and with the individual tumour responses suggest that the
tumour is the major source of circulating cytokines in patients receiving RT for advanced NSCLC.
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Introduction
Radiotherapy (RT) is the most important treatment modality
for inoperable, locally advanced non-small-cell lung cancer
(NSCLC), but conventional RT with doses in the range of 60–
70 Gy is often insufficient to eradicate the tumour, with local
control rates of only 10–20% at one year [1,2]. RT dose escalation
is a promising approach, but is limited by the low tolerance of the
surrounding normal lung tissue. Radiation pneumonitis (RP),
which represents the acute phase of radiation-induced lung injury,
is the major dose-limiting toxicity in radiotherapy for NSCLC.
The symptoms of RP range from dyspnea, cough, and fever to
death from respiratory failure. About 10–15% of NSCLC patients
develop severe lung toxicity after thoracic irradiation, and a
notable percentage of these patients die from RP [3,4,5].
Although the pathogenesis of RP remains unclear, this complex
inflammatory process involves an interplay of cellular interactions
between lung parenchymal cells and circulating immune cells
mediated through a variety of cytokines, chemokines, adhesion
molecules, etc.[6,7,8]. Animal data have shown an early
overproduction of both pro-inflammatory and pro-fibrogenic
cytokines during thoracic irradiation and have suggested a role
of the sustained production of these cytokines in the development
of acute and late pulmonary toxicities [9,10,11,12,13,14]. In
humans, some clinical reports have shown changes in the plasma
concentrations of TGF-b1 and IL-6 during RT and suggested that
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[15,16,17,18,19,20,21,22].
However, cytokines are also produced in tumours, by the tumour
cells themselves or by host stromal and immune cells of the tumour
microenvironment [23,24] This tumour-derived cytokine production
may influence the circulating plasma levels in cancer patients and
may therefore confuse the results when investigating plasma markers
for RP. There is increasing evidence that a wide variety of cytokines
are involved at every stage of the tumourigenic process [23,24].
Especially, the well-established TGF-b pathways regulate an
important network of signals that have pivotal effects on the
carcinogenic process. TGF-b plays a central role in the control of
cellular growth, differentiation and apoptosis and many tumors
escape the inhibitory function of TGF-b through mutational
inactivation of genes within the TGF-b signalling network [25,26].
During tumour progression, TGF-b induces tumour invasion and
metastasis through increasing cell motility [27]. Tumour cell
m i g r a t i o ni sac o m p l e xp r o c e s sw h i c hr e l i e so np a r t i a ld e g r a d a t i o n
of basement membranes as well as specific integrin signalling, which
enable cancer cells to detach from neighbouring cells [28]. TGF-b
and other cytokines regulate the production and activity of proteases,
capable of breaking down components of the extracellular matrix,
and therefore promoting the migratory activity of tumour cells [9,29].
Moreover, TGF-b promotes tumor vascularisation by recruiting
angiogenic factors such as vascular endothelial growth factor (VEGF)
known to activate a signalling cascade triggering angiogenesis
[30,31]. Another tumour promoting effect is the TGF-b mediated
suppression of immunosurveillance. TGF-b has been shown to
negatively regulate the functions of both cytotoxic T-cells and natural
killer cells allowing tumours to evade immunologic cell death [32].
The pro-inflammatory cytokines TNF-a, IL-1 and IL-6, by contrast,
may promote cancer progression by a variety of other mechanisms,
that are only now beginning to be elucidated [23,33]. Moreover,
TNF-a is involved in the complex and poorly understood process of
cancer-induced cachexia or muscle wasting [34]. In summary,
cytokines play a critical role in promoting tumour cell growth,
attenuating apoptosis, and facilitating angiogenesis, invasion and
metastasis. The increased production of cytokines in tumour tissues
which is launched into the blood circulation suggests the possibility of
u s i n gc y t o k i n ep l a s m al e v e l sa st u m o u rm a r k e r st om o n i t o rt h e
disease course. Actually, several clinical studies proposed the use of
cytokine plasma measurements to monitor the therapeutic effect of
RT in patients with NSCLC [35,36].
Against this background of controversial data, the present study
was designed to investigate the prognostic value of TNF-a, IL-1b,
IL-6 and TGF-b1 plasma levels to predict RP and to evaluate the
potential impact of a tumour-derived cytokine production on
circulating plasma levels in patients irradiated for NSCLC. For
this purpose, the cytokine plasma levels assessed before and during
RT were correlated with the incidence of RP. Moreover, for each
individual patient, the cytokine plasma levels measured before RT
were correlated with the cytokine production in the corresponding
tumour biopsies and cytokine plasma levels measured after RT
were correlated with the individual tumour responses of the
patients during follow-up.
Materials and Methods
Patient eligibility
Patients with medically inoperable or locally advanced NSCLC
who received radiotherapy (RT) or radio-/chemotherapy (RCT)
in our department between January 2002 and January 2005 were
enrolled onto this prospective study. Inclusion criteria were as
follows: histologically confirmed NSCLC; medically inoperable or
locally advanced NSCLC (stage I–III); no previous radiotherapy
given; Karnofsky performance status $70%; life expectancy $6
months. Protocol procedures were approved by the local ethics
committee, and all patients provided written informed consent.
Treatment description
Computed tomography (CT) based three-dimensional dose
computations were performed for all patients using the treatment
planning system ADAC Pinnacle. Target volumes (i.e. gross tumor
volume [GTV], planning target volume [PTV]) were defined
according to ICRU-50 report. PTV encompassed all visible local
and regional disease with a 1–2 cm margin based on the thoracic
CT-scan performed prior to the start of treatment. Lungs were
automatically contoured, excluding the GTV. Dose volume
histograms (DVH) of the lungs (considered as combined-paired
organ) were calculated based on CT-derived lung volumes. The
mean lung dose (MLD), as well as V20 and V30 values (irradiated
lung volume receiving more than 20 and 30 Gy, respectively) were
calculated from lung DVHs.
Thoracic RT was delivered using a linear accelerator with 6MV
and/or 23MV photons. 28 patients received curative cisplatin-
based radio-/chemotherapy (RCT): 14 patients received concur-
rent cisplatin (80 mg/m
2/d), vinorelbine (15 mg/m
2/d) and
normo-fractionated radiotherapy of 66 Gy according to the phase
II study of Vokes et al. [37]. 14 patients received concurrent
cisplatin (50 mg/m
2/d), etoposide (50 mg/m
2/d) and normo-
fractionated radiotherapy of 60 Gy according to the phase II study
of Albain et al. [38]. 14 patients not eligible for platinum-based
chemotherapy were treated with normo-fractionated radiotherapy
alone (66 Gy) (RT). 10 patients were treated according to a
palliative accelerated irradiation regimen (PAIR) with a total dose
of 32 Gy, applied in two daily fractions of 2 Gy with a time
interval of 6 hours, in a total treatment time of 10 days [39].
Circulating cytokine analysis
In each patient, serial plasma samples for TNF-a, IL-1b, IL-6
and TGF-b1 analysis were obtained before RT, once (RT/RCT)
or twice (PAIR) weekly during RT, and at every follow-up
examination (1, 3, 6 and 9 months after RT). In addition, cytokine
plasma levels were measured at the onset of symptomatic RP. To
avoid platelet degranulation, all blood samples were taken without
a tourniquet, collected in EDTA tubes, immediately chilled on ice,
and then centrifuged within 15 min of collection. TNF-a, IL-1b,
IL-6 and TGF-b1 concentrations were measured by specific
enzyme-linked immunoassay (ELISA) kits (Quantikine
TM, R&D
Systems, Minneapolis, MN, USA) according to manufacturer’s
protocol. As latent TGF-b1 was activated to the immunoreactive
form by acidification, total TGF-b1 (active and latent form) was
measured. Cytokine values determined for normal controls
(plasma samples of 20 healthy individuals) were in concordance
with previously published data from other laboratories investigat-
ing more than 400 healthy individuals with the same ELISA kits
[40]. The mean control values +2SD were regarded as cut-off
between normal and pathologically elevated cytokine levels (cut-off
values: TNF-a: 2.8 pg/ml; IL-1b: 1.63 pg/ml, IL-6: 12.5 pg/ml;
TGF-b1: 150 pg/ml). In total, 480 plasma samples were analysed
for TNF-a, IL-1b, IL-6 and TGF-b1. All measurements were
done in duplicate and mean values were used in further analysis.
Immunohistochemical staining for TGF-b1 and IL-6 in
tumour specimens
Tumour specimens (obtained by needle biopsies before
treatment) were fixed in formalin, paraffin-embedded, and
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xylene and rehydration in graded alcohols, sections were pre-
incubated with H2O2 and blocked with rabbit serum (Chemical
Credential, Aurora, Ohio, USA). Afterwards, sections were
incubated with chicken-anti-human TGF-b1 antibody or goat-
anti-human IL-6 antibody (R&D Systems; 1:30 dilution) followed
by biotinylated secondary antibody (rabbit-anti-chicken, Biomol,
Hamburg, Germany, 1:1000; rabbit-anti-goat, Dako, Glostrup,
Denmark; 1:200). Sections were labelled by avidin-biotin-perox-
idase complex (Dako), followed by diaminobenzidine (DAB,
Sigma-Aldrich, Taufkirchen, Germany) development. Finally,
sections were counterstained with haematoxylin and mounted in
Entellan (Merck, Darmstadt, Germany).
The immunoreactivity for IL-6 and TGF-b1 in the lung cancer
specimens was quantified using previously validated procedures
[41,42]: no staining (grade 0), weak but detectable focal staining
(grade 1), moderate staining (grade 2), marked staining (grade 3),
very intense staining of the tumour cells (grade 4). All lung cancer
specimens were subjected to anonymous evaluation, whereby 5–10
non-overlapping fields were analysed (magnification 6600).
Follow-up
The clinical evaluation of patients was performed weekly during
the course of RT. Follow-up examinations were performed at 1, 3,
6, and 9 months after completion of RT. Spiral CT-scans of the
chest were performed before RT, and at every follow-up
examination to monitor morphological changes in lung structure
with respect to radiation-induced lung injury and to stage
locoregional disease. If distant metastases were suspected, further
appropriate staging procedures were performed. Lung function
tests (forced expiratory volume; vital capacity; diffusion capacity,
etc.) were accomplished before RT, and at every follow-up
examination.
Evaluation of radiation pneumonitis
The occurrence and severity of RP were determined using the
LENT-SOMA scale defined by RTOG-EORTC [43]. This
evaluation includes three subjective scales (cough, dyspnea, chest
pain), two objective scales (radiological abnormalities, lung
function) and three management scales (treatment for pain, cough,
dyspnea). All single-scale measures range in score from 0 to 4 and
the final scoring (lung toxicity: grade 0/I/II/III/IV) is equal to the
average of the eight scores. RP is defined as lung toxicity $I.
Evaluation of tumour response
The evaluation of tumour response was performed according to
the Response Evaluation Criteria in Solid Tumours (RECIST)
guidelines, based on unidimensional measurement of tumour
lesions [44]. All baseline evaluations were performed close to the
beginning of treatment (#2 weeks before RT). In all patients,
spiral CT-scans of the chest -at baseline and during follow-up
examinations- have been used to measure the target lesions
selected for response assessment [45]. The response criteria for the
target lesions are: complete response (CR): disappearance of all
target lesions; partial response (PR): at least 30% decrease; stable
disease (SD): neither PR nor PD criteria met; progressive disease
(PD): at least 20% increase, or new lesion(s) [44,45].
Statistical methods
The patients’ clinical characteristics, as well as the disease and
treatment-related factors were related to the lung toxicity score
using Spearman’s correlation coefficient. The prognostic potential
of IL-6 and TGF-b1 plasma levels to predict RP was assessed in
various forms. Firstly, plasma IL-6 and TGF-b1 levels, respec-
tively, at the end of RT were divided by the corresponding pre-RT
values and on a log-scale (base 10) the ratios showed an
approximate normal distribution. The ratios (IL-6 end-RT/IL-6
pre-RT; TGF-b1 end-RT/TGF-b1 pre-RT) were related to the
lung toxicity score (grade: 0/I/II/III/IV) using Spearman’s rank
correlation coefficient and the statistical test of zero correlation.
The same procedure was repeated for the ratio obtained by
replacing the IL-6/TGF-b1 value at the end of RT by the IL-6/
TGF-b1 peak value during RT (IL-6 peak-RT/IL-6 pre-RT;
TGF-b1 peak-RT/TGF-b1 pre-RT).
The relationship between tumour response after RT and
simultaneously measured IL-6 and TGF-b1 plasma levels,
respectively, was assessed graphically using a dot plot where each
dot refers to one follow-up examination. Statistical significance of
differences between the tumour response categories (CR, PR, SD,
PD) was obtained by fitting a mixed model using the compound
symmetry assumption and the Kenward Roger method. This is an
established method to cope with irregular patterns of repeated
measurements. Statistical calculations were performed by SAS
statistical software. The criterion for statistical significance was
p,0.05. All p-values are two-sided.
Results
Patient, tumour, and treatment characteristics
52 patients with NSCLC who had tumour specimens available
for immunohistochemistry and who appeared for follow-up for at
least 6 months after completion of RT/RCT were eligible for this
study. The characteristics of the patients are summarized in table 1.
The median age was 65.1 years (range 36–85 years). Of the 52
patients, 41 (78.8%) were male and 11 (21.2%) were female. 12
patients (23.1%) had clinical stage I or II and 39 patients (75%)
had advanced stage III NSCLC. 28 patients (53.9%) received
curative RCT (normo-fractionated radiotherapy with 60–66 Gy
and concurrent cisplatin-based chemotherapy); 14 patients
(26.9%), not eligible for cisplatin-based chemotherapy, were
treated with normo-fractionated RT alone (66 Gy); 10 patients
(19.2%) were treated according to a palliative accelerated
irradiation regimen (PAIR).
Treatment toxicity
21 patients (40.4%) developed symptomatic RP according to the
LENT-SOMA scale. 14 patients showed moderate lung toxicity
with grade I in 11 patients (21.2%) and grade II in 3 patients
(5.8%). But 7 patients suffered severe lung toxicity with grade III in
6 patients (11.5%) and even grade IV in 1 patient (1.9%) (table 1).
In all patients RP was accompanied by worsening of respiratory
symptoms with deterioration of lung function parameters. In 19 of
the 21 patients with RP, radiological changes were observed in
chest CT-scans. 7 patients required corticosteroids and intermit-
tent or continuous oxygen supply. One patient developed a global
respiratory failure and needed assisted ventilation; this patient died
three weeks later due to pneumonic complications.
For this limited patient population, no significant associations
between patients’ clinical characteristics (age, gender, smoking
history) and the occurrence of RP were observed. Moreover, no
disease-related (tumour location, affected lung, clinical stage) or
treatment-related factors (concurrent chemotherapy, total radia-
tion dose, radiation fractionation, V20/V30 values) were found to
significantly predict the risk of RP in the analysed patient
population (Spearman correlation test). However, the total
number of patients is certainly to low to perform valid subgroup
analysis.
Radiation Pneumonitis
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pneumonitis
At the onset of RP, plasma levels for IL-6 and TGF-b1 were
increased in patients suffering moderate (grade I/II) and severe
lung toxicities (grade III/IV) (fig. 1). But no clear correlation
between the extent of IL-6 or TGF-b1 elevation and lung toxicity
score was observed (fig. 1). In most of the 21 patients suffering lung
toxicity, IL-6 and TGF-b1 plasma levels measured at the onset of
RP were increased compared to their individual pre-RT values (in
17 out of 21 patients for IL-6 [81.0%]; in 15 out of 21 patients for
TGF-b1 [71.4%]) (data not shown). This observation may indicate
that the inflammatory process of radiation-induced lung injury is
associated with an increased production of IL-6 and TGF-b1
within the irradiation field, which is launched into the blood
circulation leading to elevated plasma levels. Plasma concentra-
tions measured for TNF-a and IL-1b, by contrast, exhibited no
increased values at the onset of RP (fig. 1).
Cytokine plasma levels before, during and after
completion of RT
In figure 2 the cytokine dynamics are depicted separately for
patients with (lung toxicity: grade I–IV) and without RP. The
measured TNF-a and IL-1b plasma levels were within normal
ranges (as expected for healthy individuals) at nearly all times and
no significant differences between patients with or without RP
were observed. For IL-6, in contrast, the plasma levels in patients
not developing RP were already increased before and during RT.
This contrasts to previous studies [20,21], where higher IL-6 levels
were observed in patients suffering RP. After completion of RT
during follow-up (1–9 months) both patient groups (with and
without RP) exhibited slightly increased IL-6 plasma levels.
The mean values of the TGF-b1 plasma levels were clearly
increased before, during and after RT in both patient groups. A
striking observation was the large variation of the TGF-b1 plasma
levels in patients irradiated for NSCLC, which ranged from 116 to
9242 pg/ml (fig. 2). The pre-RT TGF-b1 levels were already
elevated above the cut-off ()150 pg/ml) in 47 of 52 analysed
patients (90.4%) (data not shown). For both patient groups (with
and without RP), there was a trend towards a decline of TGF-b1
levels at the end of RT (4–6 weeks) and a clear rise after
completion of RT during the follow-up (1–9 months) (fig. 2).
Collectively, no association was observed between the absolute
TNF-a, IL-1b, IL-6 and TGF-b1 plasma concentrations measured
before or during RT and the risk of RP. Thus, TNF-a, IL-1b, IL-6
and TGF-b1 plasma levels per se measured before or during the
course of RT did not allow the prospective identification of
patients at risk for RP.
IL-6 and TGF-b1 ratios and the incidence of radiation
pneumonitis
To test the hypothesis that IL-6 and TGF-b1 ratios can be used
for the identification of patients at risk as previously proposed in
the literature [15,17,18,19,20,21,22], the cytokine plasma levels
measured at the end of RT were divided by the corresponding pre-
RT values for all patients and correlated with the incidence of RP.
In figure 3, these relative values for IL-6 and TGF-b1 are plotted
separately on a base 10 logarithmic scale for the patients without
RP (grade 0), as well as for patients with moderate (grade I/II) and
severe lung toxicity (grade III/IV). Relative values .1 imply an
increase (associated with high risk for RP according to the
literature), values ,1 imply a decrease of the plasma levels at the
end of RT compared to the pre-RT levels (associated with low risk
for RP) [15,16,17,18,22]. Figure 3 illustrates that the ratios for IL-
6 and TGF-b1 were similarly distributed in all patients irrespective
Figure 1. TNF-a, IL-1b, IL-6 and TGF-b1 plasma levels at the
onset of radiation pneumonitis (mean values), depicted
separately for patients with moderate (grade I/II) (n=14) and
severe lung toxicity (grade III/IV) (n=7). Error bars represent SEs of
the means. Gray-shaded area indicates the normal range of the cytokine
plasma levels.
doi:10.1371/journal.pone.0002898.g001
Table 1. Patient characteristics.
Characteristic No. of patients %
Age, years
Median 65.1
Range 36–85
Gender
Male 41 78.8
Female 11 21.2
Clinical stage
I5 9 . 6
II 7 13.5
IIIa 13 25.0
IIIb 26 50.0
Unknown 1 1.9
Histology
SCC 27 51.9
AC 21 40.4
Others 4 7.7
Treatment
Curative RCT 28 53.9
Curative RT 14 26.9
Palliative RT 10 19.2
Radiation Pneumonitis
0 31 59.6
I 11 21.2
II 3 5.8
III 6 11.5
IV 1 1.9
doi:10.1371/journal.pone.0002898.t001
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ratios obtained by maximal plasma levels measured during RT
divided by the corresponding pre-RT values (data not shown). In
summary, we observed no statistically significant correlation
between the IL-6 and TGF-b1 ratios and the incidence of RP
(end-RT IL-6/pre-RT IL-6: r=0.08; p=0.59; end-RT TGF-b1/
pre-RT TGF-b1: r=0.04; p=0.80).
Correlation between pre-RT IL-6 and pre-RT TGF-b1
plasma levels and IL-6/TGF-b1 expression in
corresponding tumour biopsies
To evaluate the potential impact of tumour-derived cytokine
production on circulating plasma levels, the tumour biopsies of the
NSCLC patients were immunohistochemically stained for IL-6
and TGF-b1. The 52 analysed tumour specimens revealed a
heterogeneous staining pattern for IL-6 and TGF-b1 with variably
intense cytoplasmatic and/or nuclear staining of the tumour cells.
Examples of the TGF-b1 immunohistochemistry of tumour
biopsies are presented in figure 4. Compared to the rather intense
staining for TGF-b1 in most of the analyzed tumour biopsies, the
IL-6 staining of the tumour specimens was generally weaker. In
figure 5 the pre-RT plasma levels for IL-6 and TGF-b1,
respectively, were plotted against the staining intensity of the
corresponding tumour specimens for every patient. For both
cytokines a statistically significant correlation was found between
the amount of pre-RT plasma levels and the staining intensity of
the corresponding tumour biopsies, suggesting that -irrespective of
the subsequent irradiation- the IL-6 and TGF-b1 plasma levels in
NSCLC patients were influenced to a great extent by the cytokine
release of their tumours (IL-6: r=0.67, p,0.0001; TGF-b1:
r=0.83, p,0.0001).
Correlation between tumour response and IL-6/TGF-b1
plasma levels assessed at the same time-points during
follow-up
To find out whether increased IL-6 and TGF-b1 plasma levels
after completion of RT originate from the tumour, IL-6 and TGF-
b1 plasma concentrations measured at defined time-points during
follow-up were plotted against the concurrently determined
tumour responses of every patient (fig. 6). The evaluation of the
tumour response (CR, PR, SD, PD) was performed by
measurement of tumour lesions in CT-scans of the chest acquired
during follow-up (1, 3, 6, and 9 months). As shown in figure 6,
statistically significant correlations were observed between the
tumour response and IL-6 and TGF-b1 plasma levels, respectively,
assessed at the same time-points during follow-up (p=0.019 and
Figure 2. Time courses of TNF-a, IL-1b, IL-6 and TGF-b1 plasma levels (mean values) before (0), during (1–6 weeks) and after
radiotherapy (1–9 months), depicted separately for patients with (n=21) and without radiation pneumonitis (n=31). Error bars
represent SEs of the means. Gray-shaded area indicates the normal range of the cytokine plasma levels.
doi:10.1371/journal.pone.0002898.g002
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thy, for every patient at least three evaluation time-points during
follow-up (1, 3 and 6 months after RT) were included in figure 6.
Discussion
In the last years many efforts focused on the determination of
clinically useful indicators (physical and biological parameters) to
discriminate between patients with high and low risk of pulmonary
complications after thoracic irradiation for NSCLC. The ability to
select patients based on their relative risk for RP would allow the
safe delivery of higher irradiation doses in suitable patients, with
possibly improved local control and survival. Recent insights into
the pathogenesis of radiation-induced lung injury revealed a
number of biological factors which are not only involved in the
development and course of the disease but may also serve as a
predictive marker for RP. A possible link between rising cytokine
plasma levels during RT and the subsequent development of RP
has been discussed in the literature [15,16,17,18,19,20,21,22].
However, two potential sources of cytokine plasma levels have
been suggested: first, the gradually accumulating normal tissue
damage leads to an increased cytokine production within the
irradiation field, which is launched into the blood circulation.
Second, the tumour may produce variable amounts of cytokines
and, during the course of RT, cytokine plasma levels may decline,
stay elevated or even increase depending on the tumour response
to treatment [7,46].
In the present study, we investigated prospectively the dynamics
of pro-inflammatory (TNF-a, IL-1b, IL-6) and pro-fibrogenic
(TGF-b1) cytokine levels in patients irradiated for NSCLC to
ascertain their prognostic value to predict RP. Furthermore, an
attempt has been made to evaluate the potential impact of a
tumour-derived cytokine production on circulating plasma levels
which may impair the prospective identification of patients at risk
for RP. The results of our study did not confirm that TNF-a, IL-
1b, IL-6 or TGF-b1 plasma levels, neither their absolute nor any
relative values, may identify patients at risk for RP. Our results are
in accordance with the studies of Novakova-Jiresova et al. and De
Jaeger et al., demonstrating that increased TGF-b1 plasma levels at
the end of RT are not independent risk factors for developing
symptomatic RP [47,48]. Moreover, we could show that IL-6 and
TGF-b1 is produced in the tumour tissues of most NSCLC
patients to variable degree. The clear correlation between the pre-
RT plasma levels of IL-6 and TGF-b1 and the respective cytokine
production in the corresponding tumour biopsies suggests that the
elevated plasma levels in NSCLC patients result from the over-
production in their tumours. Furthermore, our data indicate a
significant association between the IL-6 and TGF-b1 plasma levels
and the individual tumour responses assessed at the same time-
points during follow-up. Based on our findings we conclude that
the tumour is a major source of circulating cytokines in patients
receiving radiotherapy for advanced NSCLC and this tumour-
derived cytokine production may impair the prospective identifi-
cation of patients at risk for RP.
Figure 3. Correlations between the IL-6 and TGF-b1 ratios and the incidence of radiation pneumonitis. For every patient, the ratios of
the plasma levels at the end of radiotherapy (end-RT) and before RT (pre-RT) are plotted logarithmically (base 10): relative values .imply an increase
(supposed high risk for RP), values ,1 imply a decrease of the plasma levels at the end of RT (supposed low risk for RP). The ratios were plotted
separately for the patients without radiation pneumonitis (grade 0) (n=31), and with moderate (grade I/II) (n=14) and severe (grade III/IV) (n=7)
lung toxicity.
doi:10.1371/journal.pone.0002898.g003
Figure 4. TGF-b1 immunohistochemistry of the tumour biop-
sies. Quantification of the staining intensity: grade 1=weak, but
detectable focal staining, grade 2=moderate staining, grade
3=marked staining, grade 4=intense staining of the tumour cells
(original magnification 6600).
doi:10.1371/journal.pone.0002898.g004
Radiation Pneumonitis
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TGF-b1 in the pathophysiology of cancer [23,33,49]. In NSCLC
cell lines IL-6 has been shown to be involved in tumour cell
proliferation, in tumour promotion and progression
[50,51,52,53,54,55,56]. In NSCLC patients elevated IL-6 plasma
levels were related to tumour size, increased with tumour
progression and have been associated with a worse prognosis
[57,58,59]. In late stages of tumour progression, TGF-b1 is known
to stimulate invasion, angiogenesis and metastasis and to inhibit
the immunosurveillance [60,61,62,63,64]. Increased plasma
concentrations of TGF-b1, due to an over-production in the
tumour tissue, have been reported in patients with NSCLC and
various other cancers [36,65,66]. Several clinical reports have
highlighted the prognostic importance of TGF-b1 in a variety of
tumours, including NSCLC, suggesting that circulating plasma
levels are correlated with the extent of disease and disease
recurrence [35,66,67,68,69].
In summary, our results indicate that monitoring plasma
concentrations of TNF-a, IL-1b, IL-6 and TGF-b1 does not
allow a predictive risk assessment for RP in patients irradiated for
advanced NSCLC. In contrast, IL-6 and TGF-b1 plasma levels
measured in patients with advanced NSCLC depend to a great
extent on the cytokine production in their tumours. Additional
release of IL-6 or TGF-b1 into the blood circulation as a result of
radiation-induced lung injury is often superimposed by the
variable cytokine production of the tumour and thus will be
difficult to detect. Hopefully, future studies will identify reliable
predictors of adverse radiotherapy effects, and thus provide the
opportunity to individualize the treatment to improve the
therapeutic outcome.
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Figure 5. Correlation between the pre-RT IL-6 and TGF-b1 plasma levels, respectively, and the IL-6 and TGF-b1 staining intensity of
the corresponding tumour biopsies (grade 1–4) (IL-6: no grade 4 samples). For both cytokines, statistically significant correlations were
found between the amount of pre-RT plasma levels and the staining intensity of the corresponding tumour biopsies.
doi:10.1371/journal.pone.0002898.g005
Figure 6. Correlation between the tumour response (CR=complete remission; PR=partial remission; NC=no change;
PD=progressive disease) and the IL-6 and TGF-b1 plasma levels assessed at the same time-points during follow-up. For both
cytokines, statistically significant correlations were observed between the tumour response categories and IL-6 and TGF-b1 plasma levels.
doi:10.1371/journal.pone.0002898.g006
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